Overview

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This clinical study will help determine if giving OGX-011 (custirsen sodium) in combination with gemcitabine (GEM) and cisplatin (CIS) or carboplatin (CARB) is a safe and effective treatment for patients with lung cancer. This study will help to assess the safety and anti-tumor effect of OGX-011 when given to patients in combination with GEM and CIS/CARB.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Achieve Life Sciences
OncoGenex Technologies
Treatments:
Gemcitabine